Top Stories
Patients with metastatic castration-sensitive prostate cancer receiving the duo achieved a radiographic progression-free survival rate of 77%.
The FDA cleared J&J's IL-23 inhibitor for structural joint damage progression and MannKind's inhaled insulin for children, while the WHO recommended Regeneron's maftivimab be prioritised in clinical development for Bundibugyo ebolavirus.
In the kappa subgroup, anselamimab improved survival by 62%.
The biotech said it has aligned with the FDA on a "path forward for resubmission and reconsideration" of a BLA for RP1.
The company said its oral PK activator still has potential as a next-generation treatment for sickle-cell disease, where Phase II topline data are due next half.
Conference News
- Late-breaking VISTAS results demonstrate rapid, sustained, and clinically meaningful reductions in pruritus with volixibat in primary sclerosing cholangitis (PSC)- Late-breaking Phase 2b AZURE-1 res...
ASCO Perspective Quote“Lymphedema can be a devastating quality-of-life issue that alters a woman's mobility, appearance, and self-esteem long after breast cancer treatment is complete. This rigorous, ...
– Updated data across two dose levels of 200 mW/cm and 400 mW/cm in LA-PDAC trial show 71% (5/7) patients resected following VTP with a consistent and well-tolerated safety profile –– Early clinical o...
– CABOMETYX significantly reduced the risk of disease progression or death by 74% and 60% in patients with non-functional and functional advanced NET, respectively, versus placebo –ALAMEDA, Calif.--(B...
– Post hoc analysis from pivotal Launch-HTN trial shows statistically significant and clinically meaningful reductions in blood pressure in participants with chronic kidney disease –– In participants ...
